Skip to content

Study · Measured the body's own peptide · 2003

2 results

MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.

Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Müller-Tidow C

Oncogene1 Sept 2003Cited by 1,852 (Europe PMC)

PMID12970751 (opens in a new tab)DOI10.1038/sj.onc.1206928 (opens in a new tab)PepBankPUB-12970751
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with early-stage non-small cell lung cancer, overexpression of thymosin beta‑4 was significantly associated with metastasis.

    In plain wordsIn people with early-stage lung cancer, higher natural thymosin beta‑4 in the tumor was linked to spread of the cancer.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseThymosin beta4 expression and metastasis in stage I NSCLC
    Study

    n = 70

    Comparator
    Tumors that did not metastasize
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Individual clones (n=225) were sequenced and quantitative RT-PCR verified overexpression in metastasizing samples. Several of the identified genes (eIF4A1, thymosin beta4 and a novel transcript named MALAT-1) were demonstrated to be significantly associated with metastasis in NSCLC patients (n=70).
    1 context sentence
    Summary · context
    In this study, we used subtractive hybridization to identify gene expression differences in stage I NSCLC tumors that either did or did not metastasize in the course of disease.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In stage I non-small cell lung cancer, thymosin beta‑4 expression was a prognostic parameter for patient survival in Kaplan-Meier analyses.

    In plain wordsIn people with stage I lung cancer, natural thymosin beta‑4 levels in the tumor were linked to survival.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableThymosin beta4 expression and survival in stage I NSCLC
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The Kaplan-Meier analyses identified MALAT-1 and thymosin beta4 as prognostic parameters for patient survival in stage I NSCLC.
    1 context sentence
    Summary · context
    In this study, we used subtractive hybridization to identify gene expression differences in stage I NSCLC tumors that either did or did not metastasize in the course of disease.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.